百特醫療 (BAX) 2016 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to Baxter International's second-quarter 2016 earnings conference call.

    歡迎參加百特國際(Baxter International)2016 年第二季財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本次電話會議由百特錄音,並屬受版權保護之資料。未經百特許可,不得錄音或轉播。如您有任何異議,請於此時中斷連線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話會議交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,您可以開始了。

  • - VP of IR

    - VP of IR

  • Thanks, Candace. Good morning. Welcome to our second-quarter 2016 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Chief Financial Officer.

    謝謝你,Candace。各位早安。歡迎參加我們 2016 年第二季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's second-quarter financial results and updated outlook for 2016, before taking your questions. I would just like to remind you, during the Q&A session, if you could please limit yourself to one question, so we can accommodate others in the queue.

    今天早上的電話會議中,我們將在回答各位問題之前,先討論百特第二季財務結果以及 2016 年最新展望。也提醒各位,在問答環節中,請盡量每人只提一個問題,以便我們能讓隊列中的其他人也有機會提問。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, and regulatory matters, contains forward-looking statements that involve risks and uncertainties. Of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning the factors that could cause actual results to differ materially.

    接下來開始我們的準備發言。我先提醒各位,本簡報(包括關於我們財務展望、新產品開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更詳細資訊。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。

  • Now, I'd like to turn the call over to Joe.

    現在,我想把電話會議交給 Joe。

  • - Chairman & CEO

    - Chairman & CEO

  • Good morning, everyone. Thanks, Clare.

    各位早安。謝謝你,Clare。

  • This is our first earnings announcement since our May investor conference. The strategies we outlined at the time are clearly gaining traction. We're making steady progress in our efforts to enhance our financial performance through our disciplined focus on portfolio and innovation management, operational excellence, and capital allocation.

    這是我們自 5 月投資人會議以來的首次財報公告。我們當時提出的策略顯然正逐步奏效。我們正穩健推進,透過對產品組合與創新管理、營運卓越,以及資本配置的紀律性聚焦,來提升財務表現。

  • As you've seen in our press release, Baxter delivered strong top-line and bottom-line results in the second quarter, exceeding expectations. I will share a few comments on our progress, and then turn it over to Jay, who will provide more details on the quarter and our updated financial outlook. After that, we will open the call for Q&A.

    如各位在新聞稿中所見,百特第二季在營收與獲利(上線與下線)皆交出強勁成果,優於預期。我將分享幾點我們的進展,接著交給 Jay,他會就本季表現與更新後的財務展望提供更多細節。之後我們將開放問答。

  • So let's get started. Baxter's worldwide sales grew 6% on a constant-currency basis and 4% on a reported basis. Sales growth was driven by strong performance in the US Fluid Systems, US peritoneal dialysis, and global acute care Renal therapies. On the bottom line, Baxter delivered adjusted earnings of $0.46 per diluted share, reflecting the benefit of better-than-expected sales growth, favorable product mix, and the positive impact of our continuing business transformation efforts.

    那我們開始吧。百特全球銷售額以固定匯率計成長 6%,以報告基礎計成長 4%。銷售成長主要由美國輸液系統(US Fluid Systems)、美國腹膜透析,以及全球急性照護腎臟治療(Renal therapies)的強勁表現所帶動。在獲利方面,百特調整後每股稀釋盈餘為 0.46 美元,反映優於預期的銷售成長、有利的產品組合,以及我們持續推動業務轉型所帶來的正面影響。

  • Now, I'll briefly walk you through the performance of our businesses and franchises, where we speak to sales growth on a constant-currency basis, excluding foreign exchange to provide a clearer picture of underlying operational performance. Global sales for Hospital Products totaled $1.6 billion, increasing 7%; excluding US cyclophosphamide sales, Hospital Products sales increased 13% in the US and 9% globally.

    接下來我將簡要說明各事業與產品線的表現;我們將以固定匯率基礎(排除外匯影響)來談銷售成長,以更清楚呈現基礎營運表現。醫院產品(Hospital Products)全球銷售額合計 16 億美元,成長 7%;若排除美國環磷醯胺(cyclophosphamide)銷售,醫院產品在美國成長 13%,全球成長 9%。

  • Now to break out Hospital Products at the franchise level. Sales in Fluid Systems were $586 million, up 15%. Growth continues to reflect the strong launch of the SIGMA SPECTRUM infusion system in the US, where we continue to gain market share, plus favorable demand and pricing in the US for IV solutions.

    接著按產品線層級拆解醫院產品。輸液系統(Fluid Systems)銷售額為 5.86 億美元,成長 15%。成長持續反映 SIGMA SPECTRUM 輸注系統在美國的強勁上市表現,我們也持續提升市占率;此外,美國靜脈輸液(IV solutions)的需求與定價亦有利。

  • Moving to Integrated Pharmacy Solutions, or IPS, sales were $563 million, increasing 4%. Growth, excluding cyclophosphamide, was up 8%, both in the US and globally, driven by solid performance across nutritional products, pharmacy injectables, and hospital pharmacy compounding services. With surgical care, which includes our anesthesia and biosurgery products, sales totaled $347 million, up 5% year over year.

    再來看整合藥局解決方案(Integrated Pharmacy Solutions,IPS),銷售額為 5.63 億美元,成長 4%。若排除環磷醯胺,成長在美國與全球皆為 8%,主要由營養產品、藥局注射劑,以及醫院藥局調配服務的穩健表現所帶動。外科照護(surgical care,包含麻醉與生物外科產品)銷售額合計 3.47 億美元,年增 5%。

  • We continue to view biosurgery as an attractive opportunity for growth through both innovation and geographic expansion. In the quarter, biosurgery sales increased mid-single digits globally. Sales continue to be impacted by lower sales of selected non-core biosurgery products, ACTIFUSE and PERI-STRIPS, which depressed growth in the quarter by approximately 2 percentage points.

    我們仍認為生物外科(biosurgery)是具吸引力的成長機會,可透過創新與地域擴張雙軌推進。本季生物外科銷售在全球呈現中個位數成長。銷售仍受到部分非核心生物外科產品 ACTIFUSE 與 PERI-STRIPS 銷售下滑的影響,使本季成長約被拉低 2 個百分點。

  • As we discussed at our May investor conference, we continue to focus on strengthening this portfolio through the introduction of new products and delivery devices, expanded indications, and continued geographic expansion. During the quarter, we expanded the launch of HEMOPATCH, our advanced surgical patch, to Brazil, Mexico, and New Zealand. HEMOPATCH provides surgeons in these markets a new, ready-to-use option that has broad indications as an advanced surgical patch.

    如同我們在 5 月投資人會議所討論的,我們持續透過導入新產品與給藥/傳遞裝置、擴大適應症,以及持續的地域擴張,來強化此產品組合。本季我們將先進外科貼片 HEMOPATCH 的上市擴展至巴西、墨西哥與紐西蘭。HEMOPATCH 為這些市場的外科醫師提供一項全新、可即用(ready-to-use)的選擇,作為具廣泛適應症的先進外科貼片。

  • Our line of inhaled anesthetics continue to lead the market globally, with second-quarter sales up 7%, globally driven by double-digit growth internationally, where we continue to leverage our array of high-quality, well-trusted anesthetics as a platform for continued geographic expansion. During the quarter, revenues in the biopharma services partnering business totaled $124 million, a decline of 5%, as expected. As previously mentioned, growth in the business has been impacted by a customer that elected to take manufacturing in-house.

    我們的吸入式麻醉劑產品線持續在全球領先市場,第二季全球銷售成長 7%,主要由國際市場的兩位數成長所帶動;我們持續運用一系列高品質、深受信賴的麻醉劑作為平台,推動進一步的地域擴張。本季生物製藥服務合作(biopharma services partnering)業務營收合計 1.24 億美元,如預期年減 5%。如先前所提,該業務成長受到一位客戶選擇將製造轉為內部自製的影響。

  • Next, turning to our Renal business, global Renal sales were $965 million, up 4%. Performance was driven by double-digit growth in our US peritoneal dialysis business work, where our highly innovative AMIA APD cycler, featuring SHARESOURCE two-way online connectivity, continues to build momentum in the marketplace. There are already more than 500 patients on AMIA in the US today, which have provided well over 30,000 treatments, taking advantage of our cloud-based platform for remote patient therapy management. In addition, during the second quarter, AMIA with SHARESOURCE was also approved in Canada, representing a new frontier for growth.

    接著看腎臟(Renal)業務,全球腎臟業務銷售額為 9.65 億美元,成長 4%。表現主要由美國腹膜透析業務的兩位數成長所帶動;我們高度創新的 AMIA 自動腹膜透析(APD)循環機,具備 SHARESOURCE 雙向線上連線功能,持續在市場上累積動能。目前在美國已有超過 500 名病患使用 AMIA,已完成逾 30,000 次治療,並運用我們的雲端平台進行遠端病患治療管理。此外,在第二季,搭載 SHARESOURCE 的 AMIA 亦獲加拿大核准,代表新的成長前沿。

  • Renal growth in the quarter also benefited from a strong growth in acute business driven by increased market adoption for continuous renal replacement therapy, or CRRT, as a treatment for acute kidney injuries. Performance in the quarter also benefited from the strong flu season and competitive supply issues. We're very excited about the opportunities for this business, which remains one of our fastest-growing areas, and an active area of focus moving forward.

    本季腎臟業務成長也受惠於急性業務的強勁成長,主要由市場對連續性腎臟替代治療(continuous renal replacement therapy,CRRT)作為急性腎損傷治療的採用率提升所帶動。本季表現亦受惠於強勁的流感季,以及競爭對手供應問題。我們對此業務的機會感到非常振奮;它仍是我們成長最快的領域之一,未來也將是我們積極聚焦的重點。

  • Our leading PRISMAFLEX platform was recently approved in China. We've initiated launch of our PRISMALUNG, low-flow carbon dioxide removal device in France, Germany, and Sweden. Growth in the in-center HD business declined in the quarter, as we continued to take a targeted approach to how we manage this business, including being selective about what market and tenders we need to participate in to support our objective of improving profitability in this business.

    我們領先的 PRISMAFLEX 平台近期已在中國獲准。我們已在法國、德國與瑞典啟動 PRISMALUNG 低流量二氧化碳移除裝置的上市。院內血液透析(in-center HD)業務本季成長下滑,因我們持續以更具針對性的方式管理該業務,包括在需要參與哪些市場與標案(tenders)上採取選擇性策略,以支持我們提升該業務獲利能力的目標。

  • Before concluding, I will share a quick leadership update. Over the past few weeks, several outstanding executives have joined Baxter's senior leadership team. These include: Giuseppe Accogli, the new appointed President of our Renal business; Stacey Eisen, our new Vice President of Corporate Communications; Scott Pleau, our new Vice President of Operations; and finally, Andy Kidd, our Vice President of Strategy and Business Development. Andy will lead Baxter's effort to accelerate activities in the area of strategy and business development to augment our growth aspirations.

    在結束之前,我先分享一則簡短的領導團隊更新。過去幾週,數位傑出的高階主管加入了百特(Baxter)的資深領導團隊。包括:Giuseppe Accogli,新任腎臟事業部總裁;Stacey Eisen,新任企業傳播副總裁;Scott Pleau,新任營運副總裁;以及最後,Andy Kidd,策略與業務發展副總裁。Andy 將帶領百特加速推動策略與業務發展領域的相關工作,以強化我們的成長企圖。

  • The entire team, those you met in May and our most recent additions, share my passion for Baxter's mission and the sense of urgency to drive transformation to pursue a top quartile performance. I have the utmost confidence in them as individuals and as a highly unified team to deliver on the potential that lies ahead for the Company and all of our stakeholders.

    整個團隊——你們在五月見過的成員以及我們最新加入的夥伴——都與我同樣熱忱於百特的使命,並抱持推動轉型、追求躋身前四分位績效的急迫感。我對他們個人以及這支高度團結的團隊充滿信心,相信他們能為公司與所有利害關係人實現未來的潛力。

  • With that, I will pass it to Jay for more details on the financials and updated outlook for 2016. Then we will have time at the end for questions. Jay?

    接下來我把時間交給 Jay,請他提供更多財務細節以及 2016 年更新後的展望。之後我們會在最後留時間回答問題。Jay?

  • - CFO

    - CFO

  • Thanks, Joe. Good morning, everyone. As Joe mentioned, we are pleased with our second-quarter results. It's another important building block as we look to achieve our long-term financial goals.

    謝謝,Joe。各位早安。如 Joe 所提到的,我們對第二季的業績表現感到滿意。這也是我們邁向長期財務目標的另一個重要基石。

  • Operationally, sales increased 6% in the quarter. On a reported basis, sales grew 4%. Growth came in 2 points above our expectations, driven primarily by favorability in Fluid Systems, acute renal, and anesthesia. Walking through the rest of the P&L, adjusted gross margin of 43.8% also compared favorably to our expectations, and was driven by a positive sales mix and improved pricing in select areas of the portfolio.

    在營運面,當季銷售成長 6%。以報表口徑計算,銷售成長 4%。成長較我們預期高出 2 個百分點,主要由輸液系統(Fluid Systems)、急性腎臟治療(acute renal)與麻醉(anesthesia)表現優於預期所帶動。再看損益表其餘項目,調整後毛利率為 43.8%,同樣優於我們的預期,主要受惠於正向的銷售組合,以及在產品組合中部分領域的定價改善。

  • Adjusted SG&A totaled $663 million, and decreased 11% on a reported basis. This represents a 440-basis-point year-over-year improvement. The primary driver of the improvement was our ongoing focus on controlling expenses and the rebasing of our cost structure.

    調整後銷售、一般及行政費用(SG&A)合計為 6.63 億美元,以報表口徑年減 11%。這代表年對年改善 440 個基點。改善的主要驅動因素是我們持續聚焦費用控管,以及成本結構的重置(rebasing)。

  • SG&A also benefited from lower pension expenses and TSA income from Baxalta/Shire. TSA income totaled approximately $30 million in the quarter compared to $20 million in the second quarter of 2015. TSA income from Shire will continue to decline, as the need for these services ramps down. We expect TSA income in the second half of 2016 to be approximately $50 million compared to $65 million in the second half of 2015.

    SG&A 亦受惠於較低的退休金費用,以及來自 Baxalta/Shire 的 TSA 收入。當季 TSA 收入約 3,000 萬美元,較 2015 年第二季的 2,000 萬美元增加。隨著對這些服務的需求逐步下降,來自 Shire 的 TSA 收入將持續下滑。我們預期 2016 年下半年 TSA 收入約為 5,000 萬美元,相較 2015 年下半年為 6,500 萬美元。

  • Adjusted R&D spending in the quarter of $150 million increased 1% versus the prior year. As we had previously announced, we discontinued our investment in the VIVIA home hemodialysis program in the second quarter, but plan to reinvest that spending into new programs in PD, biosurgery, and other initiatives to fuel future growth.

    當季調整後研發(R&D)支出為 1.50 億美元,較去年增加 1%。如先前所宣布,我們在第二季停止對 VIVIA 居家血液透析計畫的投資,但計畫將該支出重新投入至腹膜透析(PD)、生物外科(biosurgery)及其他計畫,以驅動未來成長。

  • Adjusted operating margin in the quarter was 12.3% and compared favorably to our expectations, driven by increased sales, positive product mix, and continued discipline around expense management. This represents a 530-basis-point improvement over the second quarter of 2015.

    當季調整後營業利益率為 12.3%,優於我們的預期,主要受惠於銷售增加、正向的產品組合,以及持續嚴謹的費用管理紀律。這較 2015 年第二季改善 530 個基點。

  • Interest expense was $11 million in the second quarter, reflecting the benefit of lower debt balances resulting from the utilization of the Baxalta retained stake to retire approximately $3.7 billion of gross debt. Interest expense in the quarter was also impacted by a one-time reclassification of capitalized interest from other to interest. During the second quarter, Baxter completed its disposition of the retained Baxalta equity through a contribution to its US qualified pension plan of approximately $700 million, and an equity-for-equity exchange, which reduced Baxter's outstanding share count by approximately 11 million.

    第二季利息費用為 1,100 萬美元,反映我們運用保留的 Baxalta 持股償還約 37 億美元總負債後,債務餘額下降所帶來的效益。當季利息費用亦受到一次性影響:將資本化利息自「其他」重分類至「利息」。第二季期間,百特完成處分其保留的 Baxalta 股權,包括向其美國合格退休金計畫投入約 7 億美元,以及進行股權換股(equity-for-equity exchange),使百特流通在外股數約減少 1,100 萬股。

  • Adjusted other income totaled $13 million in the quarter, and included a foreign exchange gain on balance sheet positions of approximately $3 million and dividend income of approximately $7 million associated with our former Baxalta equity stake. The adjusted tax rate was 20% for the quarter.

    當季調整後其他收益合計為 1,300 萬美元,其中包含資產負債表部位約 300 萬美元的外匯收益,以及與我們先前持有的 Baxalta 股權相關、約 700 萬美元的股利收入。當季調整後有效稅率為 20%。

  • As previously mentioned, adjusted earnings of $0.46 per diluted share exceeded our guidance of $0.38 to $0.40 per share. Relative to the mid-point of our range, this favorability was driven by approximately $0.06 of operational strength and a $0.02 benefit from interest and other income. This was partially offset by approximately $0.01, due to slightly lower-than-expected cyclophosphamide sales in the quarter.

    如先前所提,調整後每股稀釋盈餘(EPS)0.46 美元,高於我們每股 0.38 至 0.40 美元的指引。相較區間中點,優於預期主要來自約 0.06 美元的營運動能,以及利息與其他收益帶來約 0.02 美元的貢獻。部分被抵銷的因素為約 0.01 美元,原因是當季環磷醯胺(cyclophosphamide)銷售略低於預期。

  • Let me conclude my comments this morning by providing an update on our outlook for 2016. Starting with sales, on a constant-currency basis, we now expect 2016 full-year sales for Baxter to increase between 3% and 4%. After adjusting for the US cyclophosphamide impact, we expect underlying operational growth of 4% to 5%. On a reported basis, including the impact of foreign exchange, we expect sales to increase 1% to 2%.

    最後,我以更新我們對 2016 年展望作為今天上午的結語。先從銷售談起,以固定匯率(constant-currency)計算,我們目前預期百特 2016 年全年銷售將成長 3% 至 4%。若調整美國環磷醯胺的影響,我們預期基礎營運成長為 4% 至 5%。以報表口徑(包含外匯影響)計算,我們預期銷售成長 1% 至 2%。

  • We expect growth in the Hospital Products business of 3% to 4%, or 5% to 6% excluding US cyclophosphamide. Within the Hospital Products franchise, we now expect sales growth of low-double digits for Fluid Systems, driven by continued strength in the US business.

    我們預期醫院產品(Hospital Products)事業的成長為 3% 至 4%,若排除美國環磷醯胺則為 5% 至 6%。在醫院產品事業群中,我們目前預期輸液系統的銷售將呈低雙位數成長,主要由美國業務持續強勁所帶動。

  • For the Integrated Pharmacy Solutions franchise, we expect sales to decline low-single digits, including the impact of US cyclophosphamide. We've adjusted our full-year sales forecast for cyclophosphamide, and now expect full-year sales of $190 million, with the assumption that additional competitors enter the market during the fourth quarter of 2016. After adjusting for cyclophosphamide, sales are expected to increase 2% to 3% in IPS.

    就整合藥事解決方案(Integrated Pharmacy Solutions, IPS)事業群而言,我們預期銷售將呈低個位數下滑,包含美國環磷醯胺的影響。我們已調整環磷醯胺的全年銷售預測,目前預期全年銷售為 1.90 億美元,並假設在 2016 年第四季將有更多競爭者進入市場。若調整環磷醯胺影響,IPS 銷售預期將成長 2% 至 3%。

  • Within the surgical care franchise, we anticipate sales to grow 1% to 2%. Finally, for the Hospital Products business, we now expect BPS and other to decline low-single digits, reflecting a change in our manufacturing service agreement with Shire. Selected products we had previously been manufacturing on their behalf will now be transitioned to self-manufacture by Shire. For the Renal business, we now expect full-year sales to increase 3% to 4%, driven by continued growth in our PD and acute businesses, offset by lower sales in our in-center HD business.

    在外科照護(surgical care)事業群中,我們預期銷售成長 1% 至 2%。最後,就醫院產品事業而言,我們目前預期 BPS 及其他將呈低個位數下滑,反映我們與 Shire 的製造服務協議有所變更。我們先前代其生產的部分產品,將轉由 Shire 自行生產。至於腎臟(Renal)事業,我們目前預期全年銷售成長 3% 至 4%,主要由腹膜透析(PD)與急性業務持續成長所帶動,但部分被院內血液透析(in-center HD)業務銷售下滑所抵銷。

  • Moving down the P&L, we now expect an operating margin of approximately 12%, a 100-basis-point improvement versus our original guidance, reflecting increased sales and ongoing disciplined management of expenses. We expect interest expense to total approximately $80 million. For 2016, we expect other income of approximately $40 million.

    往下看損益表,我們目前預期營業利益率約為 12%,較原先指引提高 100 個基點,反映銷售增加以及持續嚴謹的費用管理。我們預期利息費用合計約為 8,000 萬美元。2016 年我們預期其他收益約為 4,000 萬美元。

  • For the year, we now expect an average adjusted tax rate of approximately 20.5% to 21%. We expect the tax rate in the second half of the year to increase, as the first half benefited from certain discrete items.

    全年而言,我們目前預期平均調整後有效稅率約為 20.5% 至 21%。我們預期下半年稅率將上升,因為上半年受惠於若干一次性項目(discrete items)。

  • For the full year, we anticipate an average share count in the range of 545 million to 550 million shares. Based on these factors, we now expect 2016 adjusted earnings, excluding special items, of $1.69 to $1.74 per diluted share, as compared to our previous guidance of $1.59 to $1.67 per diluted share. Finally, for the year, we expect operating cash flow to exceed $1.4 billion and CapEx of approximately $900 million, resulting in more than $500 million in free cash flow.

    全年而言,我們預期平均流通在外股數約為 5.45 億至 5.50 億股。基於上述因素,我們目前預期 2016 年調整後盈餘(不含特殊項目)為每股稀釋盈餘 1.69 至 1.74 美元,相較先前指引為每股稀釋盈餘 1.59 至 1.67 美元。最後,全年我們預期營運現金流將超過 14 億美元,資本支出(CapEx)約為 9 億美元,因而帶來超過 5 億美元的自由現金流。

  • Specific to the third quarter of 2016, we expect sales growth, excluding the impact of foreign currency, to increase 3% to 4%. At current foreign exchange rates, we expect reported sales to improve 2% to 3%. We expect adjusted earnings, excluding special items, of $0.43 to $0.45 per diluted share.

    針對2016年第三季,我們預期在排除外幣影響後,銷售成長將提升3%至4%。以目前匯率計算,我們預期報告銷售額將改善2%至3%。我們預期調整後盈餘(不含特殊項目)為每股稀釋後0.43至0.45美元。

  • With that, we can now open up the call for Q&A.

    接下來,我們現在可以開放電話會議進行問答。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 60 days at www.Baxter.com.

    提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供為期60天的數位重播,網址為www.Baxter.com。

  • Bob Hopkins, Bank of America.

    美國銀行的Bob Hopkins。

  • - Analyst

    - Analyst

  • Congratulations on a really strong second quarter. I will limit myself to two questions. The first one for Joe, I was wondering since it's such a topic of consideration for investors, I was wondering if you could just give us an update on the outlook for the balance sheet and M&A? What's the environment look like right now? Obviously, you have been disciplined to date, but just curious if you could give us an updated outlook for the balance sheet and M&A across the businesses. Thank you.

    恭喜第二季表現非常強勁。我會把問題限制在兩個。第一個問題給Joe:由於這是投資人非常關注的議題,想請你更新一下資產負債表與併購(M&A)的展望?目前環境看起來如何?顯然你們迄今一直很有紀律,但想請你就各事業的資產負債表與併購更新一下看法。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Bob, good morning. We don't comment specifically on targets as we want to make sure that we get there first and don't get to pay too much for them. But we are very disciplined in that area. We've been looking at a significant amount of opportunities. I just reviewed yesterday, we have probably more than 15 different opportunities in our pipeline. But I have to say that we also walked away from four deals in the last 90 days. They were too expensive. We have got to make sure that we have the discipline to execute. We could execute those deals internally. We have absolutely the right teams to get them done. But the price was too high and somebody else was willing to pay more money for that asset.

    Bob,早安。我們不會針對特定標的發表評論,因為我們希望先確保能夠達成,也避免為此付出過高的價格。但我們在這方面非常有紀律。我們一直在評估相當多的機會。我昨天剛檢視過,我們的管線中可能有超過15個不同的機會。但我必須說,過去90天我們也放棄了四筆交易。它們太貴了。我們必須確保自己有紀律去執行。我們在內部絕對有能力執行這些交易。我們完全有合適的團隊把它們做成。但價格太高,而且有其他人願意為那項資產付出更高的金額。

  • If we don't see a way there, we're not going to be competing (inaudible) scratches off deals (inaudible). I tell you, our focus is acute. We have -- having Andy Kidd as part of my operating team. Also, you raised the profile of the M&A jobs in our Company. We're working very hard to find those, as we continue to progress in creating operational opportunities for the Company as well as organic opportunities. Our balance sheet is pristine at this moment in time. So one thing about M&A, it doesn't preclude us of buying shares back. Shares back doesn't preclude us from doing M&A. I think we need to have a balanced approach. We can do probably both of them if we do it correctly.

    如果我們看不到可行的路徑,我們不會去競爭(聽不清)把交易(聽不清)。我告訴你,我們的聚焦非常明確。我們——讓Andy Kidd成為我營運團隊的一員。此外,你也提升了公司內併購職能的能見度。我們非常努力在尋找這些機會,並持續推進,為公司創造營運面的機會以及有機成長的機會。我們目前的資產負債表非常健全。因此,併購並不會排除我們回購股票。回購股票也不會排除我們進行併購。我認為我們需要採取平衡的作法。如果做得正確,我們大概可以兩者兼顧。

  • - Analyst

    - Analyst

  • Great. Thank you for that, Joe. Then, Jay, one question for you. I was just wondering if you could give us a sense of the really strong top line growth that you are generating? Can you give us a sense as to how much of that roughly is coming from price? Of the 6%, 7%, is that 1 or 2 points from price this particular quarter? Then maybe a quick comment also on just how we should be thinking about the sustainability of fluid systems growth, especially in the US? Thank you.

    很好。謝謝你,Joe。接著,Jay,我有一個問題想請教你。我想請你談談你們所帶來的非常強勁的營收(top line)成長。能否說明其中大約有多少是來自價格?在6%、7%之中,這一季是否有1到2個百分點是來自價格?另外也請簡短評論一下,我們應如何看待流體系統(fluid systems)成長的可持續性,特別是在美國?謝謝。

  • - CFO

    - CFO

  • Generally, you're right, it was a great quarter from a sales perspective. You look at businesses like the US fluid systems, as you pointed out, and we saw a north of 30% growth in the US. Just thinking about that business for a second, there's really two primary components to it. One is the infusion systems business. That's really driven by sales of the Spectrum Pump along with sales of the attendant sets. So once you install a pump, you have the sets that ride along with that. Our sets' growth in the quarter was north of 20%. Then in the infusion systems, overall growth was north of 30%.

    整體而言,你說得對,從銷售角度看這是一個很棒的季度。你看像你提到的美國流體系統等業務,我們在美國看到超過30%的成長。稍微談一下那個業務,它主要有兩個核心組成。其一是輸注系統(infusion systems)業務。這主要由Spectrum幫浦的銷售,以及配套輸注管路組(sets)的銷售所帶動。因此一旦你安裝了幫浦,就會有隨之搭配使用的管路組。我們本季管路組的成長超過20%。而輸注系統整體成長則超過30%。

  • Then on the other side, we have the IV therapy business in this particular area. That also grew north of 30%. In the case of IV therapy, it was a balanced mix of price and volume that drove the growth. The other area where we saw some pricing in the portfolio is in the area of US PD, where we did see some opportunities to capture value. But beyond that, it is a fairly stable pricing environment. I wouldn't say that there are massive or very significant changes to price beyond those two areas that I've referenced.

    另一方面,在這個領域我們還有靜脈注射(IV)治療業務。該業務也成長超過30%。就IV治療而言,成長是由價格與銷量的均衡組合所驅動。我們在產品組合中看到一些定價的另一個領域是美國PD(腹膜透析),我們確實看到一些掌握價值的機會。但除此之外,定價環境相當穩定。我不會說除了我提到的這兩個領域之外,價格有巨大或非常顯著的變化。

  • - Analyst

    - Analyst

  • But is that 1% to 2% of the total 7%, roughly the right way to think about it this quarter?

    但就這一季而言,把它理解為總體7%之中約有1%到2%來自價格,這樣想大致正確嗎?

  • - CFO

    - CFO

  • We don't really specify -- we don't really do price volume on the entire portfolio for a number of different reasons. But I think that the two areas where price was most pronounced would be in the PD arena and then also in the US infusion systems business, in the fluid systems business. The only thing I would add is, we do see some pockets of price pressure in the portfolio. So in some instances, there are offsets to price increases that we see. In certain markets, for example, where we see dialyzer pricing or other particular product areas, there are certain areas where we do see price pressures. So it is a balance. It's hard to answer the question across the board.

    我們不太會——基於多種不同原因,我們不會對整個產品組合做價格/銷量拆分的具體揭露。但我認為價格最為明顯的兩個領域,會是在PD領域,以及美國輸注系統業務(也就是流體系統業務)。我唯一想補充的是,我們在產品組合中確實看到一些局部的價格壓力。因此在某些情況下,我們看到的漲價會被其他因素所抵銷。例如在某些市場,我們看到透析器(dialyzer)定價或其他特定產品領域,確實存在一些價格壓力。所以這是一種平衡。很難用一概而論的方式回答這個問題。

  • - Analyst

    - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Vijay Kumar, Evercore.

    Evercore的Vijay Kumar。

  • - Analyst

    - Analyst

  • Congratulations on a really strong quarter. So maybe, one high-level question on the guidance. When you look at the back half, right, just given the one half performance, it seems to be a tad light in the back half, especially when you look at cyclo, the presumption is now, cyclo to impact in 4Q versus I think what we originally thought as a 3Q impact. So can you maybe just walk through some of what changes one half versus back half as we think about top line?

    恭喜本季表現非常強勁。我想就財測給一個較高層次的問題。當你看下半年時,對吧,考量上半年表現,感覺下半年的指引稍微偏保守,特別是你看cyclo(環孢素)這件事,現在的假設是cyclo會在第四季造成影響,而不是我們原先以為的第三季影響。所以你能否帶我們梳理一下,當我們思考營收(top line)時,上半年相較於下半年有哪些變化?

  • - CFO

    - CFO

  • Yes, sure. I think from the first half to the second have there are a number of drivers of change. One is we do have cyclo impact, in particular, in the fourth quarter, we'll expect to see around $40 million of year-over-year decline related to cyclo on the sales line. As it relates to other areas in terms of sales growth, we are taking a very disciplined approach across the portfolio. So as we look at areas that don't earn the right economic return for us, we will very much walk away from particular tenders or businesses.

    好的,當然。我認為從上半年到下半年,有多項驅動因素造成變化。其中之一是cyclo的影響,特別是在第四季,我們預期在營收端會看到與cyclo相關、約4,000萬美元的年對年下滑。至於其他領域的銷售成長,我們在整個產品組合上採取非常有紀律的作法。因此,當我們看到某些領域無法為我們帶來合理的經濟報酬時,我們會明確地退出特定的標案或業務。

  • So in the fourth quarter of this year, there's probably another $30 million to $40 million of low-margin sales that we choose to forgo. Then finally -- the other comment I would make on the third quarter relates to PROTOPAM last year, we did have a PROTOPAM order in the third quarter of last year that makes a tough comparable. That was about $20 million. So if you adjust for those items, I think the sales makes -- is more explainable.

    因此在今年第四季,可能還會有約3,000萬到4,000萬美元的低毛利銷售,我們選擇放棄不做。最後——我對第三季的另一點評論與去年PROTOPAM有關;去年第三季我們確實有一筆PROTOPAM訂單,使得同比比較變得困難。那筆大約是2,000萬美元。所以如果把這些項目調整掉,我認為銷售表現就——會更容易解釋。

  • Overall, as we think about the guidance on EPS in the second half, if you were to go back to last quarter's earnings call, the implied second-half guidance was $0.85 to $0.91 in earnings per share in the second half. As we think about today, our current view is $0.87 to $0.92. So essentially, we've raised the midpoint of the second-half guidance by about $0.015. What you have to realize is there are a couple of drags on the second-half number, the tax rate is slightly higher than our expectations, in part because of profitability coming in higher tax jurisdictions.

    整體而言,當我們思考下半年每股盈餘(EPS)的指引時,如果你回到上一季的財報電話會議,當時隱含的下半年指引是下半年每股盈餘0.85到0.91美元。以今天來看,我們目前的看法是0.87到0.92美元。所以基本上,我們把下半年指引的中點上調了約0.015美元。你必須了解的是,下半年數字有幾個拖累因素:稅率略高於我們的預期,部分原因是獲利更多來自高稅負司法管轄區。

  • So that's about 1 point. The share count's a little bit higher -- I should say, $0.01. Then the share count is a little bit higher as well in the second half of the year. So that's about $0.01. We do see a benefit of cyclo of about $0.01 but the ongoing organic base performance that we anticipate improving in the second half is about $0.03 relative to the last time we shared guidance. So overall, I think it's a story of continued momentum but there are some factors that do slow second half relative to first half.

    所以那大約是1個百分點。流通股數也稍微高一些——我應該說,影響約0.01美元。此外,下半年流通股數也略高。所以那大約是0.01美元。我們確實看到cyclo帶來約0.01美元的助益,但我們預期下半年持續改善的有機基礎業績,相較於上次我們提供指引時,約為0.03美元。所以整體而言,我認為這是一個動能持續的故事,但也有一些因素使得下半年相較上半年略為放緩。

  • - Analyst

    - Analyst

  • That was helpful, Jay. Just maybe a follow-up on gross margins. I know you've mentioned sales mix and pricing. Just as we sort of look at on a medium-term basis, right, if we look at new whitespace in general, a lot of your peers talk about anywhere from 50 to 200 bips of pricing headwinds. How should we think about pricing at the corporate level for Baxter on a medium-term basis? Should we think about it at net neutral? Then in the Q of gross margin, obviously, the other part was mixed, right, so as we roll profit to margin, how sustainable is some of those underlying strong gross margins trends we're seeing? Thank you.

    這很有幫助,Jay。我想再追問一下毛利率。我知道你提到銷售組合與定價。就中期來看,對吧,如果我們看一般的新市場空白(whitespace),你們許多同業都提到大約50到200個基點的定價逆風。我們應該如何在中期層面看待Baxter在公司整體的定價?是否應該視為大致持平(淨中性)?另外在毛利率的問題上,顯然另一部分是組合,對吧,所以當我們把獲利轉成毛利率時,我們看到的一些強勁的底層毛利率趨勢有多可持續?謝謝。

  • - CFO

    - CFO

  • Sure. From an overall gross margin standpoint, clearly, we were pleased with the result in the quarter. As we think about what drove margin in the second quarter and what drives it through the balance of the year, gross margin, that is, there is the price -- net price positive impact that we've seen in the quarter. So that is one element. Now, importantly, we've signed many of our agreements. We've concluded many of the agreements in a variety of our business. So as we move to next year, we don't expect to see the same level of price or economic value captured that we've experienced. But there are still some opportunities for pricing. The other element in the second quarter that was, from my standpoint, very exciting was the area of mix.

    當然。從整體毛利率的角度來看,很明顯我們對本季的結果感到滿意。當我們思考第二季毛利率的驅動因素,以及它在今年剩餘期間的驅動因素時,毛利率——也就是說——其中一項是我們在本季看到的價格(淨價格)正向影響。所以那是一個要素。而且很重要的是,我們已簽署許多協議。我們在多個業務領域已完成許多協議的談判。因此展望明年,我們不預期會看到與今年相同程度的價格或經濟價值捕捉。但在定價方面仍然有一些機會。第二季的另一個要素,從我的角度來看非常令人振奮,是產品組合(mix)。

  • So I commented earlier on 20% growth in sets. Sets carry a higher margin than the corporate average. We talked about the acute business, which was just a star performer in the quarter, That to carries a higher margin than the corporate average. We also saw good growth coming out of anesthesia and nutrition. This idea of accelerating the growth of our higher-margin products, that is something that we expect to continue for the balance of this long-range planning period. That will be one of the contributor's that takes us to our aspiration of a 17% to 18% operating margin by 2020.

    所以我先前評論過套組(sets)成長20%。套組的毛利率高於公司平均。我們也談到急性照護(acute)業務,本季表現非常亮眼;那同樣也高於公司平均毛利率。我們也看到麻醉與營養業務帶來良好成長。這種加速我們高毛利產品成長的想法,是我們預期在這個長期規劃期間剩餘時間會持續的方向。這將是帶領我們在2020年前達成17%到18%營業利益率目標的貢獻因素之一。

  • The last comment I would make is generally speaking, we saw very solid volumes in the first and second quarters. This accelerated sales growth does have a positive absorption impact on the entire manufacturing and distribution network, which allows us to benefit from higher margins by absorbing more costs. So it really was a confluence of events. We do expect to see continued margin improvements moving forward.

    我最後想補充的是,一般而言,我們在第一季與第二季看到非常穩健的出貨量。這種加速的銷售成長,對整體製造與配送網路有正向的吸收效應(absorption impact),使我們能透過吸收更多成本而受益於更高的毛利率。所以這確實是多項因素匯聚的結果。我們確實預期未來將持續看到毛利率改善。

  • Operator

    Operator

  • Mike Weinstein, JPMorgan.

    JPMorgan的Mike Weinstein。

  • - Analyst

    - Analyst

  • Congratulations as well on a very nice quarter. So, there's a couple of items, I just want to follow-up on. One, it looks like the cash flow guidance for the year has been relatively unchanged start of the year, despite obviously very significant provisions to the EPS expectations. Jay, can you just spend a minute on that. Then secondary, I just wanted to follow-up on the price discussion thus far. Thanks.

    也恭喜你們本季表現非常出色。我有幾點想再追問。第一,看起來你們今年的現金流指引自年初以來相對沒有太大變化,儘管顯然對EPS預期做了非常顯著的調整。Jay,你能否花一分鐘談談這點?第二,我也想再追問一下目前為止的定價討論。謝謝。

  • - CFO

    - CFO

  • Great. Yes, from a cash flow standpoint, you'll see in the 10-Q when we report it, we're finalizing cash flow for the quarter with PWC working very closely. But we're pleased with the second-quarter performance. What I would say, as we look for the full-year cash flow forecast is, the probability of achieving our forecast has increased based on the two quarters that we have under our belts. I'm very pleased with the performance.

    好的。是的,從現金流的角度來看,你會在我們發布10-Q時看到,我們正與PWC非常密切合作,完成本季現金流的最終結算。但我們對第二季的表現感到滿意。我想說的是,當我們看全年現金流預測時,基於我們已經完成的兩個季度,達成預測的機率已經提高。我對這個表現非常滿意。

  • At the investor day, we talked about a number of important initiatives that we are embarking on. We just started a days payable project. One of the comments I made at the investor day is, the ratio between days payable and days receivable, days held outstanding, doesn't quite work for us. It's a real opportunity. I will tell, you the early signs, that some of these projects are going very well.

    在投資人日上,我們談到多項我們正要啟動的重要計畫。我們剛開始一個應付帳款天數(days payable)專案。我在投資人日提到的一點是:我們的應付帳款天數與應收帳款天數、以及未收回天數(days held outstanding)之間的比例,對我們而言並不理想。這是一個真正的機會點。我可以告訴你,從早期跡象來看,其中一些專案進展得非常順利。

  • But the reason that we haven't changed guidance on cash flow is, a lot of our cash flow is back-end loaded due to normal seasonality patterns. Until I get a little bit better line of sight to how Q3 emerges and expectations on Q4, it is a bit premature to raise the cash flow guidance but I will tell you that the probability of achievement has increased. The other thing I will say is, we have been really focused on CapEx. So this is an area where we believe that there's opportunity for us.

    但我們之所以沒有調整現金流指引,是因為我們的現金流有很大一部分會因正常的季節性模式而集中在下半年後段。在我對第三季的走勢以及第四季的預期有更清楚的能見度之前,現在上調現金流指引還有點過早;但我可以告訴你,達成的機率已經提高。另外我還要說的是,我們一直非常專注於資本支出(CapEx)。所以這是我們認為存在機會的一個領域。

  • The 9% of sales is something that we're striving very aggressively to improve, we have long-term plans to do so. But that's another area that as we move toward the end of the year that may be another area that we update. So on balance, I feel quite good about how the cash flow story is shaping of our Company and frankly, from a free cash flow standpoint. This is a real opportunity for us not only this year but moving forward.

    資本支出占銷售額9%是我們正非常積極努力改善的項目,我們也有長期計畫要做到。但這也是另一個領域,隨著我們接近年底,可能會再更新。總體而言,我對我們公司現金流的發展態勢感覺相當良好,坦白說,從自由現金流的角度也是如此。這不僅是今年、而且是未來持續前進的一個真正機會。

  • - Analyst

    - Analyst

  • Then on the pricing discussion, if I look across the portfolio, I was hoping you could maybe just provide some more insight into the contribution from price and different businesses? Obviously, it's most pronounced in fluid systems, but the ability to take price in PD is something that relatively new for the Company. The growth of the anesthesia business this quarter was particularly strong, are you getting price there? If you could just help identify maybe the level of price you're getting in some of these businesses within hospital products? Where you are able to take price today that maybe you weren't 12 months ago? Thanks.

    接著談到定價的討論,如果我放眼整個產品組合,我希望您能就價格貢獻以及不同業務的情況提供更多洞見?顯然,在輸液系統方面最為明顯,但公司在 PD 業務上能夠提價,這相對而言是比較新的能力。本季麻醉業務的成長特別強勁,你們在那裡有提價嗎?能否協助辨識一下,在醫院產品中的某些業務,你們目前取得的價格水準大概如何?以及哪些領域是你們今天能夠提價、但 12 個月前可能還做不到的?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Mike, we have contracts that are signed very recently in the last 12 months, they're 3 to 5 years that have price clauses built into them. Okay. We look at it for trajectory of growth like fluid systems going forward. We're going to continue to see growth in that business, perhaps the rate is not the same as we took a significant amount of market share lately, but that is built into the contracts. So I feel comfortable about that. The point that you underscored about AMIA, our PD business for many years, has not experienced new technology. We have this breakthrough technology with AMIA that really had stunned the market.

    Mike,我們在過去 12 個月內剛簽署了一些合約,期限為 3 到 5 年,且內含價格條款。好的。我們會從未來成長軌跡來看,例如輸液系統往後的走勢。我們將持續看到該業務成長,或許成長率不會和我們近期大幅取得市占時一樣,但這些都已寫入合約中。所以我對此感到放心。你強調的 AMIA 這點也很重要;我們的 PD 業務多年來並未出現新技術。而 AMIA 這項突破性技術確實讓市場感到震撼。

  • We have a significant amount of providers coming to us -- the price of the product is coherent with the technology and the benefits, thanks to our patients. So we've seen some really good momentum. We see a lot of interest, not only from the providers, but from the payers side in this program, because it's selling medicine and the innovative aspect of AMIA. So we have slowed down the price erosion in dialyzers, so all in all, the Company is looking at price neutral to slightly positive going forward versus any negative price pressure or erosion. So, just again, price neutral to positive going forward.

    有大量醫療服務提供者主動找上我們——產品價格與其技術與效益相符,最終也讓病患受益。因此我們看到非常好的動能。我們也看到不僅是提供者端,連付款方(payers)也對這個方案很有興趣,因為它帶來醫療照護的價值,以及 AMIA 的創新面向。同時,我們也放緩了透析器(dialyzers)的價格侵蝕;整體而言,公司往前看在價格上將是持平到略為正向,而不是面臨任何負面的價格壓力或侵蝕。所以再重申一次,往前看是價格持平到正向。

  • - Analyst

    - Analyst

  • Joe, that comment is about your dialyzer business? Or is that a broader color?

    Joe,你這段評論是針對透析器業務嗎?還是更廣泛的說法?

  • - Chairman & CEO

    - Chairman & CEO

  • No, this is about the whole Company. The whole Company -- I see the Company when you look at all the price point analysis of what is built into contracts, the pressure in dialyzers, the AMIA launch and some of the new product launches we have, I would say, Baxter will have price neutral to positive going forward at least for the next foreseeable future.

    不,這是針對整個公司。整個公司——當你把合約中內建的條款、透析器的壓力、AMIA 的上市,以及我們的一些新產品上市等所有價格點分析放在一起看,我會說,Baxter 往前看至少在可預見的未來,價格將是持平到正向。

  • - Analyst

    - Analyst

  • Joe, that's a comment beyond 2016, right? Because in 2016, price contribution's more meaningful. --

    Joe,這個說法是超過 2016 年之後的對吧?因為在 2016 年,價格貢獻更為顯著。--

  • - Chairman & CEO

    - Chairman & CEO

  • Yes, this is beyond 2016. As I said, some of these contracts are long into the future, So this goes into 2017 as well.

    是的,這是 2016 年之後。如我所說,其中一些合約會延續到很久以後,所以也涵蓋到 2017 年。

  • - Analyst

    - Analyst

  • Perfect. Thank you, Joe.

    太好了。謝謝你,Joe。

  • - Chairman & CEO

    - Chairman & CEO

  • You're welcome.

    不客氣。

  • - CFO

    - CFO

  • Thanks, Mike.

    謝謝,Mike。

  • Operator

    Operator

  • Brooks West, Piper Jaffray.

    Brooks West,Piper Jaffray。

  • - Analyst

    - Analyst

  • I had a question on the growth trends in the US versus international. It seems like you have pretty meaningful out-performance in the US this quarter. I'm just wondering, are you seeing something in the O-US markets that's changing? Is this just a one-quarter phenomenon? I was wondering if you spend a little time on that? Then secondly, just curious what you're seeing in the O-US markets, which hit emerging market performance in Europe, et cetera. Thanks.

    我想問一下美國與國際市場的成長趨勢。看起來你們本季在美國的表現明顯優於其他地區。我想了解的是,你們是否看到美國以外(O-US)市場有什麼正在改變?這只是單一季度的現象嗎?能否花點時間談談?其次,也想請教你們在美國以外市場看到的情況,包括歐洲的新興市場表現等等。謝謝。

  • - CFO

    - CFO

  • Sure. Overall, the US did benefit from two very significant product launches, more so on the spectrum side than the AMIA side. But in the US, we are seeing the continued adoption of our spectrum version 8 pump, which is really a great innovation but also very exciting for -- from an overall financial standpoint. Then the US PD business also benefits from AMIA and also some of the execution that we're seeing overall in the US PD business.

    當然。整體而言,美國受惠於兩項非常重要的產品上市,對 Spectrum 端的影響更大,AMIA 端相對較少。但在美國,我們看到 Spectrum 第 8 版幫浦持續被採用,這確實是一項很棒的創新,從整體財務角度來看也非常令人振奮。此外,美國的 PD 業務也受惠於 AMIA,以及我們在美國 PD 業務整體執行面所看到的一些改善。

  • Then finally, the acute businesses has seen outstanding growth in the US, in part benefiting from a flu season that extended and was a bit more acute than we previously expected. So there were a number of factors that set the conditions up for success in the US that allowed us to over-achieve our expectations and deliver the 10% growth. Outside the US, we reported 3% growth internationally. What I would say is, emerging markets roughly mid single-digits growth.

    最後,美國的急性照護業務也出現了出色的成長,部分原因是流感季延長,且比我們先前預期更為嚴重。因此有多項因素共同創造了美國成功的條件,使我們能夠超越預期並交出 10% 的成長。在美國以外,我們國際市場報告為 3% 成長。我會說,新興市場大約是中個位數成長。

  • We did have lower growth in China in the quarter. So low single-digits in large part, you'll recall, we exited certain tenders for PD, where the margins weren't attractive to us. So there was that overhang on our overall business in emerging markets and in China. We do expect to sunset that after this quarter. So, we'll see an acceleration, we expect to see, in emerging markets in the Q3, Q4 timeframe. So those would be a few of the overall comments I would make on that.

    本季我們在中國的成長較低。因此是低個位數成長,主要原因是你會記得,我們退出了某些 PD 的標案(tenders),因為其毛利對我們沒有吸引力。所以這對我們在新興市場以及中國的整體業務造成了一些拖累。我們預期在本季之後會讓這個影響逐步消退。因此,我們預期在第三季、第四季期間,新興市場的成長會加速。以上是我對此會做的幾點整體評論。

  • - Analyst

    - Analyst

  • That's helpful. Then on the bio-surgery business, if I could, it looked like a nice step up in performance there. I'm wondering, is that just getting the portfolio straightened out? Is it underlying volumes? Any detail there would be helpful. Thanks.

    這很有幫助。接著如果可以的話,關於生物外科(bio-surgery)業務,看起來表現有不錯的提升。我想了解,這只是把產品組合梳理順了嗎?還是來自於基本面量的成長?任何細節都會很有幫助。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • A couple of things. One was focus, make sure that we are on global basis focusing on that business. We have great portfolio and I think other things were taken precedence. Second thing was we launched HEMOPATCH as well. In our efforts there, it's time to ramp up. I have to tell you, we're in the process of a very -- the final stages of hiring a President, a global President for bio-surgery, which creates a vertical for this business on the global basis.

    有幾個因素。第一是聚焦,確保我們在全球範圍內都把重點放在這項業務上。我們有很好的產品組合,但我認為過去有其他事情被優先處理。第二是我們也推出了 HEMOPATCH。就我們的推動而言,現在正是放量爬坡的時候。我必須告訴你,我們正在進行一項非常——目前已到最後階段——的招募,將聘任一位生物外科的全球總裁,為這項業務在全球建立一條垂直管理線。

  • It creates a very different focus in our Company for bio-surgery, which is a very different product than the rest of our portfolio and requires a significant amount of detailing into accounts. So that associated with us doubling the amount of R&D going into bio-surgery is, and also two or three potential smaller cases is that can go into this business, it will revitalize our bio-surgery business and put us on track to over perform.

    這會讓公司對生物外科有非常不同的聚焦;它與我們產品組合中的其他產品非常不同,且需要在客戶端進行大量的學術推廣與帳戶深耕。因此,配合我們將投入生物外科的研發(R&D)加倍,以及另外兩到三個可能納入此業務的較小案例,將能重振我們的生物外科業務,並讓我們走上超越表現的軌道。

  • - Analyst

    - Analyst

  • Great. Thanks, guys.

    很好。謝謝各位。

  • Operator

    Operator

  • David Lewis, Morgan Stanley.

    David Lewis,Morgan Stanley。

  • - Analyst

    - Analyst

  • Two quick questions for Joe or Jay. The first one's on US fluid systems, so I'm looking at that said performance here in the quarter. It looks like about half the organic growth of the business is coming from just the US fluid systems business, about 3.5%. So Jay, can you sort of walk us through anything you can tell us on mix of capital and consumables? How that contracting sort of falls forward into 2017? What you think the structural growth rate for this business is on a longer-term basis? Then I had a quick follow-up on guidance.

    給 Joe 或 Jay 兩個簡短問題。第一個是關於美國輸液系統;我在看本季這裡的表現。看起來該業務的有機成長中,大約有一半是來自美國輸液系統業務本身,約 3.5%。所以 Jay,你能否帶我們了解一下你能分享的資訊:資本設備與耗材的組合(mix)如何?這些合約在 2017 年的延續情況如何?以及你認為這項業務在更長期基礎上的結構性成長率會是多少?然後我還有一個關於財測指引(guidance)的追問。

  • - CFO

    - CFO

  • Yes. I mean, look, overall, fluid systems business, we anticipate over the next five years to be a 3% to 4% grower, although, I look at this particular quarter and it's a very solid data point in terms of growth and adoption that we were pleased with. Thinking about the performance of the business, it's important to decompose it into a couple of different segments, right? One is the IV business. We are working very hard to bring additional volumes to the market. We're very focused on delivering. So as we think about the sustainability of this particular aspect, this should be a steady grower for the next several years. In part because of the contracts that we've discussed but also in part because of continued volume that we look to bring to the US.

    是的。我的意思是,你看,整體而言,流體系統業務,我們預期未來五年將以 3% 到 4% 的速度成長;不過,我看這一季本身,在成長與採用方面是一個非常扎實的數據點,我們對此感到滿意。談到這項業務的表現,把它拆解成幾個不同的區塊來看很重要,對吧?其中之一是 IV 業務。我們正非常努力把更多的量帶到市場上。我們非常專注於交付。因此,當我們思考這一塊的可持續性時,未來幾年它應該會是穩定的成長動能。部分原因是我們討論過的合約,另外部分原因是我們預期持續把更多的量導入美國。

  • In the other roughly half of the business, the infusion systems area, there's two component pieces to this. The larger one today, relates to pump sales. So we've had great success with pump business. We continue to perform in line with the expectations or better than with the expectations that we've shared with investors over the last year on pump placements. But then the other benefit is as we place pumps, going with those pumps is a non-capital sale. That's the set piece, right?

    在業務的另一個大約一半,也就是輸注系統領域,這裡有兩個組成部分。目前較大的那一塊與幫浦銷售有關。因此我們在幫浦業務上取得了很大的成功。在幫浦裝機(placements)方面,我們持續表現符合、甚至優於過去一年我們與投資人分享的預期。但另一個好處是,當我們配置幫浦時,隨著這些幫浦而來的是非資本性銷售。那就是耗材組件(set),對吧?

  • So our sets were up, as I said earlier north of 20% in the quarter, just a very solid element. This becomes more of an annuity or an ongoing stream of business that's related to pumps. So I would say that's a more sustainable business than the capital sales, which are a little bit lumpier in nature if you will. Overall, though, we feel confident that the business will grow, I believe north of 10% on full-year basis globally, Then moving forward for the next five years, this 3 to 4 kind of mid single-digits type growth is what we can expect to see from fluid systems.

    所以我們的耗材組件(sets)如我先前所說,本季成長超過 20%,這是一個非常扎實的要素。這會更像是一種年金式或持續性的業務流,與幫浦相關。因此我會說,這比資本設備銷售更具可持續性;資本銷售的特性會比較不均勻、比較有波動。不過整體而言,我們有信心這項業務在全球以全年基礎來看將成長超過 10%。接著往後看未來五年,流體系統預期可見的就是這種 3% 到 4% 的中等個位數成長。

  • - Analyst

    - Analyst

  • Jay, very, very helpful. Then second, just to reconcile the fourth quarter number, My way of thinking about it is, maybe you plant a 2%, 2.5 % constant currency for the fourth quarter and then we sort of add back 1.5 point from cyclo and 1.5 from the discontinued operations you talked about. That kind of gets you back to 5%, 5.5%, which is sort of consistent with the first half? Is that sort of a decent way of thinking about the fourth quarter?

    Jay,非常、非常有幫助。第二個問題,關於第四季數字的對帳:我的想法是,第四季你可能先假設 2%、2.5% 的固定匯率成長,然後我們再把你提到的 cyclo 加回 1.5 個百分點,以及你談到的已停止營運加回 1.5 個百分點。這樣大概就回到 5%、5.5%,也就是與上半年大致一致?這樣理解第四季算是合理嗎?

  • - CFO

    - CFO

  • That's exactly how we look at there. So we had about 1.5 points for cyclo. I wouldn't characterize it as discontinued operations. But for us, we're going to be very disciplined about sales. We will forgo sales in certain incidents that don't make sense. That's about a 1.5 point of half of impact, in that case though, that's a very low margin impact. As you know, the cyclo on the other hand is a higher margin impact.

    我們的看法完全就是那樣。所以 cyclo 大約是 1.5 個百分點。我不會把它描述為已停止營運。但對我們而言,我們會在銷售上非常自律。在某些情況下,若不合理,我們會放棄銷售。那大約是 1.5 個百分點的影響;但在那個案例中,那是非常低毛利的影響。如你所知,另一方面 cyclo 則是較高毛利的影響。

  • - Analyst

    - Analyst

  • Great. Thank you very much. Great quarter.

    很好。非常感謝。這一季表現很棒。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Matt Miksic, UBS.

    Matt Miksic,瑞銀(UBS)。

  • - Analyst

    - Analyst

  • So one follow-up for you, Jay, on gross margin. So, very strong in the quarter at least relative to our estimate. I'd love to get some additional, anything you can quantify around some of the puts and takes there by sort of business line or product line. I mean, based on David's question, it looks like even through those sets, for example, they started to pick up growth. You're not quite growing as fast as capital in infusion systems. So is that reflecting some of the strength here? Or cyclo some of the strength? Just maybe take through the business lines, then maybe you can talk a little bit about that. Then I have a follow-up for Joe.

    我有一個追問,Jay,關於毛利率。本季毛利率非常強勁,至少相對於我們的估計而言。我想再多了解一些,你能否就各業務線或產品線的正負因素(puts and takes)做一些量化說明。我的意思是,根據 David 的問題,看起來即使是例如那些耗材組件(sets),它們也開始回升成長。你在輸注系統中,成長速度沒有資本設備那麼快。所以這是否反映了這裡的一些強勁表現?或者是 cyclo 的一些強勁表現?也許你可以按業務線帶我們走一遍,然後再談談這點。之後我還有一個問題要問 Joe。

  • - CFO

    - CFO

  • Sure. Just from a gross margin for the quarter, actually cyclo was below our expectations by a little bit. There were a variety of reasons, but it was not meaningful. But when you talk about missing cyclo sales relative to expectations by $5 million, $7 million. That has an impact on both gross margin and EPS. So the margin that we saw was even in excess from a pure operational standpoint, but, look, there are two primary factors, right? One is price. So we did see some price benefit in the quarter. But another and again, this is the more sort of exciting area as I look at the business is the area of mix.

    當然。就本季毛利率而言,其實 cyclo 略低於我們的預期。原因有很多,但影響不大。不過當你談到 cyclo 的銷售相對預期少了 500 萬到 700 萬美元時,這會同時影響毛利率與 EPS。因此我們看到的毛利率,從純營運角度來看其實更高;但你看,主要有兩個因素,對吧?第一是價格。所以本季我們確實看到一些價格帶來的好處。但另一個——而且就我看這也是更令人振奮的部分——是產品組合(mix)。

  • So when you have: our sets business; our acute business, which is $400 million business; our anesthesia business, which is I believe north of $700 million; our nutrition business, which is also a very healthy sized business for us. When you have roughly 20% of your portfolio growing at a faster rate than the corporate average and when that has a much higher average margin than the corporate average, it really is a benefit that you see on the gross margin line. In our case, that's something that we experienced in the second quarter.

    所以當你有:我們的耗材組件(sets)業務;我們的急性照護(acute)業務,規模約 4 億美元;我們的麻醉(anesthesia)業務,我相信超過 7 億美元;我們的營養(nutrition)業務,對我們而言規模也相當可觀。當你的產品組合中約有 20% 的部分,其成長速度快於公司整體平均,而且其平均毛利率也遠高於公司整體平均時,這確實會反映為毛利率線上的好處。在我們的情況下,這是我們在第二季所經歷到的。

  • Now turning to the rest of the year, we do expect to see some of that continued benefit from the accelerated growth of those higher-margin businesses. But then there's also a secondary impact, which I referenced earlier, which is as you -- as your plans fill up with incremental volume, there is additional absorption that is occurred, the manufacturing network becomes more utilized. So you do see unintended absorption benefit on the cost profile, which also impacts margin. So, second quarter, great, you see price and mix [plane] coming to bear, moving forward, we'll have price, mix and volume. That's why we've been able to increase the guidance in the second half of the year.

    接著看今年剩餘時間,我們確實預期會持續看到那些高毛利業務加速成長所帶來的一些延續性效益。但還有第二個影響,我先前也提過:當你——當你的工廠因新增產量而更滿載時,就會產生額外的吸收(absorption),製造網絡的利用率會提高。因此你會在成本結構上看到非預期的吸收效益,這也會影響毛利率。所以第二季很好,你看到價格與組合 [plane] 開始發揮作用;往後看,我們會有價格、組合與產量。這也是為什麼我們能夠在下半年上調指引。

  • - Analyst

    - Analyst

  • Great. Thanks. The follow-up for Joe. You'd mentioned when we were out to see you, these initiatives sort of reinvigorating the entrepreneurial spirits of some of the teams across Baxter, as one of the things you've been focusing on. I'd love to get your perspective, if you could spend a few minutes just on the progress there. Specifically on, what we'll see from that? The types of benefits you hope and expect to see in terms of growth and margins? When maybe we start to see some of that blow through?

    很好。謝謝。接著追問 Joe。你提到我們去拜訪你們時,這些計畫正在重新激發 Baxter 各團隊的創業精神,這是你一直在聚焦的事情之一。我想請你分享一下你的觀點,如果可以的話,花幾分鐘談談目前的進展。特別是,我們會從中看到什麼?你希望並預期在成長與毛利率方面看到哪些類型的效益?以及大概什麼時候我們會開始看到這些效益反映出來?

  • - Chairman & CEO

    - Chairman & CEO

  • We have a pretty structured program. We have somebody in charge of that who reports directly to Paul Vibert, our President of International. A couple notable, as we just launched a pain pump in Italy, in Europe, that was a local initiative. The elastomeric business is active outside the US. We didn't have the right product for parts of Europe, we just launched that. So it could pick up good margin and sales for the group. We also have a plan to bring China to $1 billion by 2021, which is now much shorter than that in our LRP, so that brings growth up to close to 10%.

    我們有一個相當結構化的計畫。我們有一位負責人,直接向我們的國際事業總裁 Paul Vibert 匯報。幾個值得一提的例子:我們剛在義大利、在歐洲推出了一款止痛幫浦,那是地方性的倡議。彈性體(elastomeric)業務在美國以外也很活躍。我們過去在歐洲部分地區沒有合適的產品,現在剛推出。因此它可以為該團隊帶來不錯的毛利與銷售。我們也有一個計畫,要在 2021 年前把中國做到 10 億美元;而在我們的長期規劃(LRP)中,現在距離那個時間點更近了,因此可把成長拉升到接近 10%。

  • So we're very excited about that. That was all done local, China for China, a significant amount of change in directions and mix of products with parts of the business refocusing attrition for China, which is a great opportunity and introducing bio-surgery in China, which we don't have today. So these are just two examples. I can give you a great example in Brazil and Colombia, we'll be launching our ringer product with big sales in three years of $15 million, a highly profitable.

    所以我們對此感到非常興奮。這些都是在地完成的,中國為中國;在方向與產品組合上做了相當幅度的調整,讓部分業務重新聚焦於中國的自然流失(attrition),這是一個很好的機會,並且在中國導入我們目前尚未有的生物外科(bio-surgery)。所以這只是兩個例子。我也可以給你一個在巴西與哥倫比亞的很好的例子:我們將推出我們的林格液產品,三年內可望帶來1,500萬美元的大額銷售,且獲利能力很高。

  • So we have significant amount of programs going on in the Company to sustain organic growth, driven by a more disciplined and cadence of launching products and have products available for the rest of the world. We didn't do particularly a good job in launching products on a global basis. We have reinvigorated that. We have so many good products and good invention and innovation in house. So those are really exciting and creating momentum in the Company.

    因此,公司內有相當多的計畫正在進行,以維持有機成長,這些計畫由更有紀律、且更有節奏的產品上市所驅動,並讓產品能供應到世界其他地區。過去我們在全球範圍推出產品這件事上做得並不是特別好。我們已經重新振作並強化了這一點。我們內部有非常多優秀的產品,以及很好的發明與創新。所以這些都非常令人振奮,並在公司內部形成動能。

  • - Analyst

    - Analyst

  • Thanks.

    謝謝。

  • Operator

    Operator

  • Glenn Novarro, RBC Capital Markets.

    Glenn Novarro,RBC Capital Markets。

  • - Analyst

    - Analyst

  • It's more of a back row question. Your fluid systems, your hospital products business all grew very strongly in the US and very specific to the Company in your execution. But I was wondering if in the second quarter you saw any favorable macro trends? In other words, did you see any pick-up in hospital admissions or surgical volumes? I wonder if you can speak to and address the health of the US market in general, Joe? Thank you.

    這比較像是一個後排的問題。你們的輸液系統、醫院產品業務在美國都成長得非常強勁,而且這很大程度上是公司執行力的結果。但我想請問,在第二季你們是否看到任何有利的總體趨勢?換句話說,你們是否看到住院人次或手術量有所回升?Joe,你能否談談並說明一下整體美國市場的健康狀況?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • We see a slight uptick in the procedure volume, probably 3% and 4% growth in the US. This is a good thing for us, with the fluid systems being driven primarily by debt. Also a good flu season helped, was important this year for use of fluids and pumps. We see the environment in the US is stable. Not with a trajectory of growth that we probably saw before, but with growth, as we see unemployment still subdued and below, sub 5%. So it's a good trend for the country and continuing.

    我們看到手術/處置量略有上升,在美國大概是3%到4%的成長。這對我們是好事,因為輸液系統主要是由債務(debt)所驅動。另外,今年流感季表現不錯也有幫助,對輸液與幫浦的使用很重要。我們看到美國的環境是穩定的。雖然成長軌跡不像我們之前看到的那樣,但仍有成長;因為我們看到失業率仍然受控,低於5%。所以這對國家而言是一個良好趨勢,並會持續下去。

  • - Analyst

    - Analyst

  • Just on an unrelated -- I just wanted to get back to Bob's question on M&A. I believe on -- it was handled at the analyst day or one of the previous calls, you talked about integrated pharmacy solutions. That's a business on the M&A front. I believe you used the words, you wanted to double down. You also just mentioned on this call that there were four deals that you just passed up on in the last 90 days. So were some of these deals in integrated pharmacy solutions? Why has the dynamic become so competitive of late? Thank you.

    另外一個不相關的問題——我想回到Bob關於併購(M&A)的問題。我記得在分析師日或之前某次電話會議上,你們談到整合式藥局解決方案(integrated pharmacy solutions)。那是一個在併購面向的業務。我記得你用過「想要加碼投入(double down)」這樣的字眼。你也在這通電話中提到,過去90天你們剛放棄了四筆交易。所以這些交易中有一些是在整合式藥局解決方案領域嗎?為什麼最近競爭態勢變得這麼激烈?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • You're welcome, ahead of answering my question. I would say to you that there are very few areas of growth if you think about healthcare and about the targets. The multiples in EBITDA are skyrocketing in some areas, go figure out why. I just saw a couple of deals. One that just got concluded in the US, on the front end, generics company. The multiples are extremely high for -- in capability more than anything else because the Company did not make any products. So we have those capabilities in-house. We look at some of these deals and we don't see the price, the coherence between price and value.

    不客氣,你在我回答問題之前就先說了。我會這樣跟你說:如果你從醫療保健以及標的的角度來看,真正有成長的領域其實不多。某些領域的EBITDA倍數正在飆升,至於原因你可以自己去研究。我剛看到幾筆交易。其中一筆剛在美國完成,是前端的學名藥公司。倍數非常高——主要是買能力(capability),而不是其他,因為那家公司並不生產任何產品。而我們這些能力在內部就有。我們看一些交易時,會覺得價格與價值之間缺乏一致性。

  • I think, when we don't see the coherence and it does not meet our expectations, we have very established guidelines with our Board, they reflect our best interest of our shareholders. I would say will not step into those deals. We walked away from another deal that had a significant difference between us and a foreign party who was trying to buy the company. There's not a deal that is important enough that will make us spend our shareholders money in vain. So we're going to continue to pursue the couple deals on the table right now that we think are actionable. We're pursuing them, but we're going to always keep our eyes on value.

    我認為,當我們看不到這種一致性、而且不符合我們的期待時,我們與董事會有非常明確的準則,這些準則反映了股東的最佳利益。我會說,我們不會踏入那些交易。我們也曾退出另一筆交易,因為我們與一個試圖收購該公司的外國買方之間存在顯著的價差。沒有任何一筆交易重要到值得我們徒然花費股東的資金。因此,我們會持續推進目前桌面上我們認為可執行的幾筆交易。我們正在推進,但我們永遠會把價值放在首位。

  • - Analyst

    - Analyst

  • Okay. Thanks, Joe.

    好的。謝謝,Joe。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Danielle Antalffy, Leerink.

    Danielle Antalffy,Leerink。

  • - Analyst

    - Analyst

  • Congrats on an excellent quarter. Jay, I was wondering if you could talk about Brexit and the impact both on sales overall but specifically, as it relates to FX, your exposure to the UK?

    恭喜你們交出非常出色的一季。Jay,我想請你談談英國脫歐(Brexit)及其影響:不僅是對整體銷售的影響,尤其是就外匯(FX)而言,你們對英國的曝險如何?

  • - CFO

    - CFO

  • Great. Thanks for the question. Overall from volume standpoint, we don't expect an impact from some of the macro challenges we're seeing in Europe. Most of our product lines are more steady stream from a unit standpoint. So we don't really anticipate an impact in that sense. From a foreign exchange standpoint, really, we have a number of hedges and opportunities that we have. So as it relates to the UK, we have roughly 5% of our sales in the UK. We do have a manufacturing plant in the UK that provides a natural hedge against fluctuations in that currency.

    好的。謝謝你的問題。整體從量的角度來看,我們不預期歐洲目前看到的一些總體挑戰會造成影響。我們大多數產品線在單位數量方面都比較屬於穩定型。因此在這個意義上,我們不太預期會有影響。就外匯而言,我們確實有多項避險與可運用的機會。以英國來說,我們約有5%的銷售來自英國。我們在英國也有一座製造工廠,能對該貨幣波動提供天然避險。

  • Then in the euro zone area, we have a number of plants. So as the euro moves, we do have natural offsets to sales -- the currency fluctuations in that market as well. But the other thing that we do is, we use synthetic hedges or derivatives, principally, options to hedge foreign currency exposure. We have a well-disciplined approach where we hedge out up to five or six quarters; we hedge roughly 20% per quarter. We use options, which really caps the downside associated with those instruments.

    另外在歐元區,我們有多座工廠。因此當歐元波動時,我們在該市場的銷售——也就是匯率波動——也有天然的對沖抵銷。但我們做的另一件事是使用合成避險或衍生性商品,主要是用選擇權(options)來對沖外幣曝險。我們有一套紀律嚴謹的方法,會把避險拉到未來五到六個季度;每一季大約避險20%。我們使用選擇權,能有效封頂這些工具所帶來的下行風險。

  • Now for us, as we evaluated the Brexit situation leading up to that particular event, we actually did a couple things, we increased our exposure or increased our derivative positions on the pound and increased our derivative positions on the euro as well, as an insurance policy to ensure that there would be no adverse impact this year or next year. So the result of that is, despite the movement in the pound and the euro, we really offset some of the translational impact of the P&L with gains associated with those derivatives that we put into place.

    對我們而言,在評估脫歐事件、並在該事件發生之前,我們其實做了幾件事:我們提高了對英鎊的曝險、也提高了對歐元的衍生性部位,作為保險措施,以確保今年或明年不會有不利影響。因此,儘管英鎊與歐元出現波動,我們仍能透過這些已建立的衍生性商品所帶來的收益,抵銷損益表(P&L)在換算上的部分影響。

  • We are very pleased with the situation that we're currently in. The other item that we did is, as the yen strengthened, we did take the opportunity to increase some of our exposure, again, using options, so that the downside is limited to the yen. So we had some of our incremental yen positions at basically JPY100 to $1, again, a trade that we were pleased with and situated us well for both this year and next year from a foreign exchange risk standpoint.

    我們對目前所處的狀況非常滿意。我們做的另一件事是,當日圓走強時,我們也把握機會再次使用選擇權提高部分曝險,讓日圓的下行風險受到限制。因此,我們新增的一些日圓部位基本上是在1美元兌100日圓(JPY100 to $1)的水準,同樣是一筆我們很滿意的交易,從外匯風險角度來看,讓我們在今年與明年都處於良好位置。

  • - Analyst

    - Analyst

  • Okay. That's really helpful. If I could follow-up, one more macro question following up on Glenn's question about US volumes. Ex-US, there's a little bit more uncertainty, turmoil if you want to call it that, in emerging markets and both -- also in Europe, just wondering what you're seeing from a volume trend -- procedure volume trend, ex-US? Whether that's offsetting some of the strength we're seeing here in the US? Thanks so much.

    好的。這非常有幫助。如果可以追問一下,延續Glenn關於美國量的問題,我還有一個總體問題。在美國以外,無論是在新興市場,或是——也包括在歐洲——不確定性與動盪(如果你想這麼稱呼)更高;想請問你們在美國以外看到的量的趨勢——手術/處置量的趨勢——是什麼?這是否在抵銷我們在美國看到的一些強勁表現?非常感謝。

  • - Chairman & CEO

    - Chairman & CEO

  • There is a very high diversity of scenarios. So you have China with -- it's a pretty stable market regarding our products, the products we serve the Chinese market in terms of pricing. But you always have the trend of risk of price controls and things like that. But we see of China with a pretty stable outlook, as well some parts of Latin America, even Brazil, depending on -- independently of the currency situation. You still have Brazil with good prospects for growth, Columbia, Mexico. I would say when we move away from emerging markets, developed markets such as Australia with very strong growth, good performance.

    情境的多樣性非常高。所以你看中國——就我們的產品而言,對中國市場供應的產品在定價方面是一個相當穩定的市場。但你總是會看到價格管制之類的風險趨勢。不過我們認為中國的展望相當穩定,拉丁美洲的部分地區也是如此,甚至巴西也一樣,這取決於——且不受匯率情況影響。巴西仍然有良好的成長前景,哥倫比亞、墨西哥也是。我會說,當我們離開新興市場、轉向已開發市場時,例如澳洲,成長非常強勁、表現良好。

  • We see markets there for areas like hospital admissions. But we see that via our compounding business there that is doing very well, no issues. I would say Europe is always a point of attention, with very slow growth in most of the five large countries in Europe, with some exceptions in parts of probably, England and Spain, we see little bit of growth there. But it's a market that we are being very careful in how we compete. We are very disciplined in pricing, but we see that market a bit more tenuous than the rest of the developed markets.

    我們在那裡看到像是住院收治等領域的市場機會。但我們透過當地的配製(compounding)業務來看,表現非常好,沒有問題。我會說歐洲一直都是需要關注的重點,歐洲五大國中多數國家的成長非常緩慢,但也有一些例外,可能在英國和西班牙的部分地區,我們看到些許成長。但這是一個我們在競爭方式上非常謹慎的市場。我們在定價上非常自律,但我們認為該市場相較於其他已開發市場更為脆弱一些。

  • - Analyst

    - Analyst

  • Very helpful. Thank you.

    非常有幫助。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • You're welcome.

    不客氣。

  • Operator

    Operator

  • Larry Keusch, Raymond James.

    Larry Keusch,Raymond James。

  • - Analyst

    - Analyst

  • Joe, I wanted to come back to emerging markets. I think if I have got the math right, you have probably some somewhere in the 4%-ish range growth in the first half of the year. I think on the first-quarter call, you were talking about more like 9% to 10% growth for 2016, after you do some adjusting for a renal situation in China. So, I wanted to see if the thoughts around that kind of high single-digit growth, 9%, 10% are still in place? If so, what gets you from that kind of 4%-ish range to 9%, 10% for the year.

    Joe,我想回到新興市場的話題。如果我算得沒錯,你們上半年成長大概在4%左右。我記得在第一季電話會議上,你們談到2016年在針對中國腎臟相關情況做一些調整後,成長大概會是9%到10%。所以我想確認一下,對於那種高個位數成長、9%、10%的看法是否仍然成立?如果是,那麼要如何從約4%的區間提升到全年9%、10%?

  • - Chairman & CEO

    - Chairman & CEO

  • The 9%, 10% for the year is towards the back-end of the year. Then we also have China being the biggest drivers. So think about the size of China for our business is over $600 million in sales. That drives a lot of the numbers when you look at emerging markets and primarily Asia. China, there was -- we walked away from an unprofitable bid last year for PD patients. Because we lost those patients, the impact was felt this year in the first and second-quarter anniversary -- just anniversaried. So we're going to see a recovery in China by the third and fourth quarter, which subsequently will create the momentum for the growth rate that we have outlined.

    全年9%、10%是偏向於下半年後段的表現。另外,中國也是最大的驅動因素。所以想想看,中國對我們業務的規模,銷售額超過6億美元。當你看新興市場、尤其是亞洲時,這會驅動很多數字。在中國,我們去年退出了一個對PD病患而言不具獲利性的投標案。因為我們失去了那些病患,其影響在今年第一季與第二季的同期間比較中反映出來——剛好完成同比基期。因此我們將在第三、第四季看到中國的復甦,進而帶動我們所提出的成長率動能。

  • - VP of IR

    - VP of IR

  • Yes. Overall, Larry, what I would say is that we expect emerging market growth for the full-year, in line with the guidance that we provided at our May investor conference of around 5% to 6%. So that's kind of the outlook for the full year. As Jay referenced earlier, there are certain markets and products that we're going to be exiting or not participating in those tenders. A lot of those are in emerging markets. That impact will be in the fourth quarter. So that will depress growth in the fourth quarter in emerging markets. But overall, will grow in line with that guidance that we outlined in May.

    是的。整體而言,Larry,我會說我們預期新興市場全年成長將與我們在5月投資人會議所提供的指引一致,約為5%到6%。這就是全年展望。如同Jay先前提到的,有些市場與產品我們將退出,或是不參與那些標案。其中很多都在新興市場。那個影響會在第四季顯現。因此會壓低新興市場第四季的成長。但整體而言,仍會依照我們5月所提出的指引成長。

  • - Analyst

    - Analyst

  • Okay. Terrific. That's very clear. Then lastly, just on CRRT, obviously the growth has been very impressive. I was wondering if you can deconstruct that a little bit as to what's really driving that? Is that market share gain? Is it increasing use of the therapy? How do we think about the runway for that growth? How sustainable is it?

    好的。太好了。非常清楚。最後,關於CRRT,顯然成長非常亮眼。我想請你們稍微拆解一下,究竟是什麼在驅動?是市占率提升嗎?是療法使用量增加嗎?我們該如何看待這個成長的跑道?它有多可持續?

  • - Chairman & CEO

    - Chairman & CEO

  • It is all the above. So the way to deconstruct and see the underlying growth for acute renal care, which uses CRRT technology to be at 10%, 11% growth business. We have benefited from a couple things. One is we've been gaining market share from other [modalities] on top of the growth of the usage of that technology. We can see that by the sales of equipment, by sales of capital. So when we have the sales of capital being increased, we know that the pull-through will happen, but we need to be at the hospitals to make sure that technology is used instead of flat or something else. So it's a very good underlying market growth.

    以上皆是。所以如果要拆解並看急性腎臟照護(使用CRRT技術)的內生性成長,這是一個約10%、11%成長的業務。我們受惠於幾件事。第一,我們在該技術使用量成長之上,還從其他[治療模式]那裡取得了市占率。我們可以從設備銷售、資本設備銷售看出來。當資本設備銷售增加時,我們知道後續耗材拉動(pull-through)會發生,但我們需要在醫院端確保該技術被使用,而不是維持持平或改用其他方式。所以這是一個非常好的內生市場成長。

  • Second is there was a supply issue in the marketplace, primarily, in the US. Baxter is always there for our customers. We were able to supply product for our patients. By doing it so we were able to help our hospitals as well as create some momentum and potential conversion opportunities of those accounts, because not all of them probably will go back to the original manufacture, who was in that quarter and short in the market. So we will be able to pick that up in the near future. So it is a great business for us; hence, our ability to continue to tag other technologies like PRISMALUNG and the other things that we spoke of in May at our investor day, because it's a real door opener into the ICU for us.

    第二,市場上曾出現供應問題,主要在美國。Baxter一向都在那裡支持我們的客戶。我們能夠為病患供應產品。透過這麼做,我們得以協助醫院,同時也創造了一些動能,以及這些客戶轉換的潛在機會,因為其中並非所有客戶都可能回到原本的製造商——那家廠商在那一季供應不足、在市場上短缺。因此我們在不久的將來能夠承接這部分需求。所以這對我們而言是一個很棒的業務;也因此我們能持續把PRISMALUNG等其他技術,以及我們在5月投資人日所談到的其他項目串聯起來,因為它對我們而言是真正打開ICU大門的切入點。

  • - VP of IR

    - VP of IR

  • The only other thing I would add too, is the first half of the year really benefited from a strong flu season that we don't expect that to repeat in the second half of the year. So that's why the growth in the acute will kind of come down to the levels that Joe referenced earlier in terms of the underlying market growth rate.

    我唯一想補充的是,上半年其實也受惠於強勁的流感季,但我們不預期下半年會重演。所以急性業務的成長會回落到Joe先前提到的、就內生市場成長率而言的那些水準。

  • - Analyst

    - Analyst

  • Okay. Terrific. Thank you.

    好的。太好了。謝謝。

  • Operator

    Operator

  • Joanne Wuensch, BMO.

    Joanne Wuensch,BMO。

  • - Analyst

    - Analyst

  • Terrific quarter and good morning. When I take a look at your third-quarter guidance and full-year guidance and we back into the fourth quarter, it looks like you're looking at about 2%, ex-FX. Some of that, I suspect is cyclo, some of that is probably flu because it's not going to be there, but how would we sort of peel away that somewhat lower organic revenue growth rate versus what you just delivered in the second quarter?

    這一季表現很棒,早安。當我看你們第三季指引與全年指引,並回推到第四季時,看起來你們預期約2%的成長(不含匯率影響)。其中一部分我猜是cyclo,一部分可能是流感因素,因為下半年不會再有,但我們要如何拆解這個相對較低的有機營收成長率,相較於你們第二季剛交出的表現?

  • - CFO

    - CFO

  • Sure. There's two factors. One is cyclo, which is about 1.5 points. This year, the biggest year-over-year impact will be in the fourth quarter, as we assume the entrance of a couple of new competitors to that business. So it's about $40 million or 1.5 points. The other item is, it's more of a sales than profit impact, but we regularly look at our portfolio and we'll walk away from certain sales that are below a margin threshold. In the case of Q4, as we planned and expected, there are certain things that we are walking away from that will impact the fourth quarter by about 1.5 percentage points as well. So in combination, those two items yield roughly 3 points of growth to the fourth quarter.

    好的。有兩個因素。第一是cyclo,約1.5個百分點。今年同比影響最大的會在第四季,因為我們假設該業務會有幾個新競爭者進入。所以大約是4,000萬美元或1.5個百分點。另一項因素,對銷售的影響大於對獲利的影響,但我們會定期檢視產品組合,並會放棄一些低於毛利門檻的銷售。以第四季而言,依照我們的規劃與預期,我們將放棄某些項目,這也會使第四季受到約1.5個百分點的影響。因此合併起來,這兩項因素合計約為第四季帶來約3個百分點的成長差異。

  • - Analyst

    - Analyst

  • That makes sense. Thank you. Then as my follow-up question, the US fluid system's number is so wonderfully strong. How do we get that going outside the United States? Not that I'm asking for more, but just asking. Thank you.

    這很有道理。謝謝。那麼作為我的追問,美國輸液系統的數字表現非常強勁。我們要如何在美國以外把這項業務推動起來?我不是在要求更多,只是想請教。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Well, we have a very nice base of pharmacy installed outside the US still, with significant amount of channels. We, through partnerships right now in a strong group, work with our partner who will be able to launch products in the future, not too far. They will start replacing our fleet outside the west and continue to growth with more variety and different types of pumps. But we need to sustain that business.

    嗯,我們在美國以外仍然有相當不錯的藥局端裝機基礎,且通路覆蓋相當可觀。目前我們透過合作夥伴關係,在一個強大的合作群組中,與能在不久的將來推出產品的合作夥伴一起運作。他們將開始在西方以外地區替換我們的機隊,並以更多樣化、不同類型的幫浦持續成長。但我們需要維持這項業務的可持續性。

  • I think that was key. As we look back and thought about the priorities -- you asked us to a big priority (inaudible) some pumps. But as we have seen this traction going and we have new versions coming up from product development, it's for us now to focus outside the US with our global product line. I think we have that strategy and the products line now to do so, so we'll be coming out soon with new products that will create momentum outside the US and protect our base.

    我認為那是關鍵。回顧並思考優先事項時——你們曾要求我們把一個很大的優先事項放在(聽不清)一些幫浦上。但隨著我們看到這股動能持續,以及產品開發即將推出新版本,對我們而言,現在要把重點放在美國以外、以我們的全球產品線來推進。我認為我們現在已具備這樣的策略與產品線,因此很快會推出新產品,在美國以外創造動能並鞏固我們的基礎。

  • - CFO

    - CFO

  • Joanne, the only other comment to add is, in the second quarter, growth was adversely impacted because we had a shipment to a particular country, Canada, last year of pumps, so it was more of a -- it was a [bullish] order that we had that impacted growth several percentage points in the fluid systems business. So that negative 1%, we actually saw a mid single-digit growth in IV therapy, which was a solid performer in the quarter, but we did have the overhang of that one order.

    Joanne,另外補充一點:第二季的成長受到不利影響,因為去年我們曾向某個國家——加拿大——出貨一批幫浦,所以這比較像是——我們當時有一筆[看多]訂單,對輸液系統業務的成長造成了幾個百分點的影響。因此那個負1%,其實我們在靜脈輸液治療(IV therapy)看到的是中個位數成長,該業務在本季表現穩健,但確實受到那一筆訂單的拖累。

  • - Analyst

    - Analyst

  • Thank you so much.

    非常感謝。

  • Operator

    Operator

  • Matt Keeler, Credit Suisse.

    Matt Keeler,瑞士信貸。

  • - Analyst

    - Analyst

  • Just a couple of quick ones. First the -- now that the retained stake utilization has been completed, where there any changes versus your prior thinking to the P&L guidance?

    我有幾個很快的問題。首先——既然保留持股的處置已經完成,與你們先前的想法相比,對損益表(P&L)指引是否有任何變化?

  • - VP of IR

    - VP of IR

  • Our P&L guidance, any changes to our P&L guidance?

    我們的損益表(P&L)指引,對我們的P&L指引有任何變化嗎?

  • - CFO

    - CFO

  • No, broadly in line. Look, we were very pleased with the execution of the retained stake. Frankly, the tax treasury and legal team here Baxter worked very hard in the face of the Shire transaction to execute on those transactions in a timely manner, exactly as we expected it. So from our standpoint, a broad brush, we had anticipated about $0.15 of impact this year. We'll experience $0.15 of impact this year. We're very thankful and appreciative of all the hard work that allowed us to get to that stage.

    沒有,整體而言大致一致。你看,我們對保留持股的執行非常滿意。坦白說,Baxter 這邊的稅務、財務與法務團隊在 Shire 交易的背景下仍非常努力,按時完成這些交易,結果完全符合我們的預期。因此就我們的角度,以概括來說,我們原先預期今年約有0.15美元的影響。我們今年也將承受0.15美元的影響。我們非常感謝並肯定所有人的辛勤工作,讓我們能走到這一步。

  • - Analyst

    - Analyst

  • Just to wrap it up, the reallocation has spend from VIVIA to PD and bio-surgery. Any more color you can give us on where that spending will go? Is there any impact there to the -- either revenue or expense guidance for the year?

    最後一個:資源重新配置,支出從 VIVIA 轉到 PD 和生物外科。你們能否再多提供一些細節,這些支出會用到哪些地方?這對今年的——不論是營收或費用指引——是否有任何影響?

  • - Chairman & CEO

    - Chairman & CEO

  • A couple of examples, we have several but we will give three to you. One is we're going to be launching a variant of our offsets outside the US that we need, so someone is going there. Then we're doubling the R&D dollars going into bio-surgery, just launched several different programs in bio-surgery. Lastly, our point of care is now being fully funded as we are planning to come into the US in about three years with a new point of care to provide patients with on-demand manufacture of peritoneal dialysis, a solution in the home.

    舉幾個例子,我們有好幾項,但先提供三個。第一,我們將在美國以外推出我們某些配套/選配的變體版本,這是我們所需要的,因此會有人力與資源投入那裡。第二,我們把投入生物外科的研發資金加倍,並且剛啟動了數個不同的生物外科專案。最後,我們的即時照護(point of care)現在已獲得完整資金支持,因為我們計畫約三年後進入美國市場,推出新的即時照護方案,讓病患能在家中按需製造腹膜透析用的溶液。

  • So a quick use of that money. That's one of the reason that didn't -- would not flow through the bottom line, we have just better use of the money. Very consistent with our capital allocation policy, as well as we see great opportunity across the board in many organic opportunities. One last to mention is IPS, actually we accelerated all the molecules that were out, slated for 2019, 2020, 2021 to come earlier. That program costs money. We're funding that as well with some of the [PTM] money. So a great organic opportunity in the Company, could not pass the opportunity of putting money in the right places.

    所以這筆錢很快就會被運用。這也是其中一個原因,為什麼它不會——不會流到損益表的最終淨利端:我們只是把錢用在更好的地方。這與我們的資本配置政策非常一致,同時我們也看到公司在多個有機成長機會上都有很大的潛力。最後再提一項是 IPS:我們其實把原本排在2019、2020、2021推出的所有分子(molecules)都加速提前。那個計畫需要資金。我們也會用部分[PTM]的資金來支持。公司內部有很好的有機機會,我們不能錯過把資金投放到正確位置的機會。

  • - VP of IR

    - VP of IR

  • Thanks, everyone.

    謝謝各位。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for your participation. Have a great day.

    各位女士先生,今天與 Baxter International 的電話會議到此結束。感謝各位的參與。祝各位有美好的一天。